Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Franco AT Israel DA

    2020-08-28


    26. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L, Perez-Perez GI, Hatakeyama M, Whitehead R, Gaus K, O’Brien DP, Romero-Gallo J, Peek RM Jr. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A 2005;102:10646–10451.
    27. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, Blagg J, Aherne W, Dale T. A useful approach to identify novel small-molecule in-hibitors of Wnt-dependent transcription. Cancer Res 2010;70:5963–5973.
    29. Ishimoto T, Izumi D, Watanabe M, Yoshida N, Hidaka K, Miyake K, Sugihara H, Sawayama H, Imamura Y, Iwatsuki M, Iwagami S, Baba Y, Horlad H, Komohara Y, Takeya M, Baba H. Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa. J Gastroenterol 2015;50:751–757.
    30. Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:196–219.
    31. Butcher LD, den Hartog G, Ernst PB, Crowe SE. Oxida-tive stress resulting from Helicobacter pylori infection contributes to gastric carcinogenesis. Cell Mol Gastro-enterol Hepatol 2017;3:316–322.
    32. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group. Effect of eradication of Heli-cobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lan-cet 2008;372:392–397.
    33. Nakajima T, Oda I, Gotoda T, Hamanaka H, Eguchi T, Yokoi C, Saito D. Metachronous gastric cancers after endoscopic resection: how effective is annual endo-scopic surveillance? Gastric Cancer 2006;9:93–98.
    expression
    in gastric cancer. Int J
    poor prognostic marker in early gastric cancer, but not in
    advanced gastric cancer. Cancer Res Treat 2016;
    36. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A,
    Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M,
    Campbell LL, Polyak K, Brisken C, Yang J,
    Weinberg RA. The epithelial-mesenchymal transition
    generates G-15 with properties of stem cells. Cell 2008;
    37. Zavros Y. Initiation and maintenance of gastric cancer: a
    focus on CD44 variant isoforms and cancer stem cells.
    38. Vaira D, Malfertheiner P, Megraud F, Axon AT,
    Deltenre M, Hirschl AM, Gasbarrini G, O’Morain C,
    Garcia JM, Quina M, Tytgat GN. Diagnosis of Heli-
    cobacter pylori infection with a new non-invasive anti-
    gen-based assay. HpSA European study group. Lancet
    tion and grading of gastritis. The updated Sydney Sys- 1856
    tem. International Workshop on the Histopathology of 1857
    Correspondence
    Address correspondence to: Hidekazu Suzuki, MD, PhD, FACG, AGAF, RFF,
    Department of Gastroenterology and Hepatology, Tokai University School of
    Acknowledgments
    The authors are shoot grateful to the Collaborative Research Resources, School of 1869
    Medicine, Keio University, for technical assistance.
    Author contributions
    Hitoshi Tsugawa and Hidekazu Suzuki conceived the study and planned the
    experiments; Hitoshi Tsugawa, Chihiro Kato, Hideki Mori, and Kaori
    Kameyama performed the experiments; Hitoshi Tsugawa, Hideki Mori, 1873
    Juntaro Matsuzaki, Hideyuki Saya, Masanori Hatakeyama, Makoto
    Suematsu, and Hidekazu Suzuki analyzed the data; and Hitoshi Tsugawa,
    Hideki Mori, Juntaro Matsuzaki, and Hidekazu Suzuki wrote the manuscript. 1875
    Con fl
    icts of interest
    This author discloses the following: Hidekazu Suzuki has received scholarship 1877
    funds from Daiichi-Sankyo Co, EA Pharma Co, Otsuka Pharmaceutical Co Ltd, 1878
    and Tsumura Co to conduct research, and has received service honoraria from
    Astellas Pharm, Inc, Astra-Zeneca KK, Daiichi-Sankyo Co, EA Pharma Co,
    Otsuka Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Tsumura Co, 1880
    Mylan EPD Co, and Zeria Pharmaceutical Co Ltd. The remaining authors
    disclose no conflicts.
    Funding This work was supported by Grants-in-Aid sfor Scientific Research (C) Q41882
    supported program for the Strategic Research Foundation at Private Q24
    Contents lists available at ScienceDirect
    Gynecologic Oncology
    Cancer susceptibility gene mutations in type I and II endometrial cancer☆,☆☆
    a Mayo Clinic, Division of Gynecologic Oncology, United States of America
    b Mayo Clinic, Department of Epidemiology, United States of America
    c Mayo Clinic, Department of Biostatistics, United States of America